IL6 and arthritic joint disease: Application of sCD83 not only reduced the clinical symptoms of arthritis, but also inhibited the antigen-specific T cell proliferation upon mBSA-restimulation and impaired production of key inflammatory effectors, including IL-17A, TNFα, IFNγ, and IL-6.